Mon, January 17, 2011
Fri, January 14, 2011
[ Fri, Jan 14th 2011 ] - Market Wire
ICON Acquires Oxford Outcomes
Thu, January 13, 2011
Wed, January 12, 2011
Tue, January 11, 2011
Mon, January 10, 2011
[ Mon, Jan 10th 2011 ] - Market Wire
Teleflex Acquires VasoNova Inc.
[ Mon, Jan 10th 2011 ] - Market Wire
30 A.M. ET
Sun, January 9, 2011
Fri, January 7, 2011
Thu, January 6, 2011
Wed, January 5, 2011
Tue, January 4, 2011
Mon, January 3, 2011
Fri, December 31, 2010
Thu, December 30, 2010
Wed, December 29, 2010
Tue, December 28, 2010
Mon, December 27, 2010
Fri, December 24, 2010
Thu, December 23, 2010
Wed, December 22, 2010
Tue, December 21, 2010
Mon, December 20, 2010
Fri, December 17, 2010
Thu, December 16, 2010
Wed, December 15, 2010
Tue, December 14, 2010

AVEO Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference


//health-fitness.news-articles.net/content/2011/ .. 9th-annual-j-p-morgan-healthcare-conference.html
Published in Health and Fitness on Tuesday, January 4th 2011 at 10:00 GMT by Market Wire   Print publication without navigation


CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at 10:00 a.m. (PST) at the Westin St. Francis Hotel in San Francisco. Mr. Ha-Ngoc is expected to present an overview of the company and updated financial guidance.

A live webcast of AVEOa™s presentation can be accessed by visiting the investors section of the companya™s website at investor.aveopharma.com. A replay of the webcast will be archived on the AVEO website for two weeks following the presentation.

About AVEO

AVEO Pharmaceuticals (NASDAQ: AVEO) is a cancer therapeutics company committed to discovering, developing and commercializing targeted therapies to impact patientsa™ lives. The companya™s lead product candidate, tivozanib, is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in patients with advanced renal cell carcinoma, as well as additional clinical studies in other solid tumor types. AVEOa™s second most advanced product candidate, AV-299, is a potent, functional anti-HGF/c-MET pathway antibody that is currently in Phase 2 clinical development. AVEOa™s proprietary Human Response Platforma" offers the company a unique advantage in cancer drug development and has provided a discovery engine for high-value therapeutic targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets including HGF, ErbB3, RON, Notch and FGFR. For more information, please visit the companya™s website at www.aveopharma.com.


Publication Contributing Sources